Virtual Library
Start Your Search
Mehmet Ali Nahit Sendur
Author of
-
+
P1.01 - Advanced NSCLC (Not CME Accredited Session) (ID 933)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
-
+
P1.01-45 - Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey (ID 14012)
16:45 - 18:00 | Author(s): Mehmet Ali Nahit Sendur
- Abstract
Background
ALK mutation is observed in 4% of patients diagnosed with NSCLC. The present study aimed to evaluate the efficacy of crizotinib, an ALK inhibitor, and clinical characteristics of ALK-positive NSCLC patients.
a9ded1e5ce5d75814730bb4caaf49419 Method
In this multicenter, retrospective study, data of ALK-positive advanced stage NSCLC patients who received crizotinib were retrieved from hospital records.
4c3880bb027f159e801041b1021e88e8 Result
Data of 353 ALK-positive metastatic NSCLC patients receiving crizotinib in any treatment line were analyzed. The mean age of the patients was 53.2±12.6 years [median, 53 years (21-85 years)] and 193 (54.7%) patients were male. Age at diagnosis was significantly higher in males than in females (54.8±11.8 years and 51.3±13.2 years, respectively; p=0.044). The rate of patients who never smoked was 50.1%. The most common histological subtype was adenocarcinoma (96%). The frequency of brain metastasis at the time of diagnosis was 23.4%. The most common initial symptoms were cough (56%) and dyspnea (53%). Initial ECOG score was 0 or 1 in 80% of the patients. Crizotinib had been used in 37% of the patients in the 1st-line treatment, in 45% of the patients in the 2nd-line treatment, and in 18% of the patients in the ≥3rd-line treatment.
Table 1. Response rates of the patients
Treatment line
Overall
N (%)1
N (%)2
N (%)3
N (%)Other
N (%)Complete response
28 (7.9)
9 (7.3)
14 (8.9)
4 (9.8)
1 (5.6)
Partial response
217 (61.5)
78 (62.9)
103 (65.2)
25 (61.0)
10 (55.6)
Stable disease
50 (14.2)
18 (14.5)
21 (13.3)
7 (17.1)
4 (22.2)
Progressive disease
67 (13.3)
19 (15.3)
20 (12.7)
5 (12.2)
3 (16.7)
Undefined
11 (3.1)
ORR
245 (69.4)
87 (70.2)
117 (74.1)
29 (70.8)
11 (61.2)
DCR
295 (83.6)
105 (84.7)
138 (87.4)
36 (87.1)
7 (83.4)
Undefined
11 (3.1)
ORR was 69.4% and DCR was 83.6% (Table 1). ORR and DCR in the patients received crizotinib were 70.2% and 84.7% in the 1st-line treatment, respectively and were 74.1% and 87.4% in the 2nd-line treatment, respectively. The frequency of brain metastasis was 40.2% at 12 months. Of these patients, the median PFS and OS were 11.3 and 28.0 months, respectively.
The most common side effects were fatigue, visual disturbances, nausea, abdominal discomfort, and pretibial edema.
8eea62084ca7e541d918e823422bd82e Conclusion
Clinical characteristics of ALK-positive patients and crizotinib efficacy are consistent with studies. Response rates and survival outcomes are similar regardless of treatment lines. Crizotinib is safely used in these patients.
6f8b794f3246b0c1e1780bb4d4d5dc53
-
+
P2.01 - Advanced NSCLC (Not CME Accredited Session) (ID 950)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.01-83 - Evaluation of Dynamic Thiol/Disulphide Homeostasis in Advance Non-Small Cell Lung Cancer and Small Cell Lung Cancer (ID 13804)
16:45 - 18:00 | Presenting Author(s): Mehmet Ali Nahit Sendur
- Abstract
Background
The complicated pathogenesis of lung cancer is the mainstay of all its different histological subtypes. Oxidative stress has detrimental effects on chronical diseases as well as cancer. Thiol groups which have high antioxidant capacity, turn to disulpide (DS) groups with biochemical reactions that neutralize different oxidant compounds. Thiol/Disulpide homeostasis (TDH) has significant effects on cell mechanisms, transcription and apoptosis. Here, we present the role of dynamic TDH in both advanced non-small cell (NSCLC) and small cell lung cancer (SCLC) patients.
a9ded1e5ce5d75814730bb4caaf49419 Method
The patients who diagnosed with NSCLC and SCLC between 2015 and 2017 prospectively analysed. Serum samples of the patients obtained at the time of diagnosis and after first-line treatment. TDH tests were measured by the automated spectrophotometric method.
4c3880bb027f159e801041b1021e88e8 Result
57 patients (43 NSCLC and 14 SCLC) and 50 healthy controls enrolled to study. There was no statistical difference in age (median 61 and 60.5) and sex status between groups.Native thiol (NT) and total thiol (TT) levels were significantly lower in the patients’ group (Table 1).DS/NT ratio which is the best indicator of antioxidant capacity reached statistical significance between NSCLS patients and controls (p=0.04). After median 27.2 months follow-up,median overall survival (OS) was 9.5 months in NSCLC and 12.3 months in SCLC groups.Thiol or DS variables had no effect on survival.13 of the 30 patients had progressive disease after first-line chemotherapy. DS levels and DS/NT ratio were lower in patients after progression compared with levels at the time of diagnosis (p=0.013 and 0.033).
8eea62084ca7e541d918e823422bd82e ConclusionVariable Patients
Median (min-max)Controls
Median (min-max)p Native Thiol 358 (215-3261) 429 (313-607) <0.001 Disulpide 20.8 (0.05-55) 20 (8.4-37) 0.98 Total Thiol 398 (253-573) 464 (354-632) <0.001 Disulpide/ Native Thiol 0.05 (0.01-0.19) 0.05 (0.02-0.14) 0.08
Lower levels of thiol groups may contribute to lung cancer pathogenesis as a result of enhanced oxidative stress.The deficiency of this antioxidant compounds may relate to structural damage of signal, transcription, apoptosis mechanisms in lung cancer cell lines. The lower levels of DS and DS/NT ratio after progression may be an indicator of the high tumor volume and enhanced cell turnover.
6f8b794f3246b0c1e1780bb4d4d5dc53
